INDIVIDUAL TEST 247
PLA2R Antibodies ELISA (IgG)
Indication
Suspicion of primary membranous nephropathy (PMN)
Sample material
Serum
- Minim. volume: 0,5 mL
Transport
- Within Sweden: room temperature
- International: room temperature
Method
ELISA
Reference interval
< 14 RU/mL negative, 14-19 RU/mL borderline
Result
Results are reported as negative, borderline or positive with a concentration.
Interpretation
Antibodies against PLA2R is a strong marker for primary membrane nephropathy (PMN) and occur in serum of 75% of these patients. The levels are usually higher than borderline. The antibodies lead to complement-activating immune complexes on the basal membrane in glomeruli causing tissue damage and proteinuria. Higher levels of antibodies are associated with increased disease activity and monitoring the antibodies levels can be used to follow treatment effect.
References
- Ronco P, Debiec H. Lancet. 2015. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. PMID: 26090644
- Larsen CP et al. Mod Pathol. 2016. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. PMID: 26847174
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int. 2024. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. PMID: 38490803
- Rovin BH et al. Kidney Int. 2021. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. PMID: 34556300
Last updated: 2025-10-09
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 247
PLA2R-antikroppar ELISA (IgG)
Indikation
Misstanke om primär membranös nefropati (PMN)
Provmaterial
Serum
- Minim. volym: 0,5 mL
Transport
- Inom Sverige: rumstemperatur
- Internationellt: rumstemperatur
Metod
ELISA
Referensintervall
< 14 RU/mL negativt, 14-19 RU/mL gränsvärde
Resultat
Resultat anges som negativt, gränsvärde eller positivt med koncentration.
Tolkning
Antikroppar mot PLA2R är en stark markör för primär membranös nefropati (PMN) och förekommer hos 75% av dessa patienter. Vanligtvis ses högre antikroppsnivåer än gränsvärden. Antikropparna leder till komplementaktiverande immunkomplex på basalmembranen i glomeruli med vävnadsskada och proteinuri som följd. Högre nivå av antikropparna är kopplad till ökad sjukdomsaktivitet och monitorering av antikroppsnivån är av värde för uppföljning av behandlingseffekt.
Referenser
- Ronco P, Debiec H. Lancet. 2015. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. PMID: 26090644
- Larsen CP et al. Mod Pathol. 2016. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. PMID: 26847174
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int. 2024. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. PMID: 38490803
- Rovin BH et al. Kidney Int. 2021. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. PMID: 34556300
Senast uppdaterat: 2025-10-09